Multifactorial analysis of the dependence of prescribed diagnostic test systems and purchased targeted drugs on the example of lung adenocarcinoma in St.P.

Aim. to conduct a pharmacoeconomic analysis of the correlation between prescribed diagnostic test systems and purchased targeted drugs used for the treatment of non-small cell lung cancer with a mutation in the EGFR gene.

Materials and methods. The materials for this study were the data of the Unified Information System in procurement
and the analytical database AlphaRM. Statistical data processing was carried out using MS Excel 2019.

Results and discussion. As a result of the study, a comparative analysis of the prescribed drug therapy was carried out in patients with non-small cell lung cancer with a mutation in the EGFR gene. It was revealed that at the moment the most effective drug is osimertinib, the appointment of which should be prescription by a molecular genetic study to justify the purchase due to the high cost of the drug. In 2020, a separate standard for the state guarantees program was introduced for conducting research. However, the analysis revealed differences in the purchase of targeted drugs and prescribed diagnostic studies.

Conclusion. Based on the results of the analysis, it was concluded that the currently existing system of drug provision for oncological patients requires the creation of unified mechanisms that allow for the reasonable purchase of targeted drugs by increasing molecular genetic testing in medical institutions, as well as rational use of state budget funds. As part of the state registration procedure and on the basis of clinical and economic analysis, it is necessary to determine the types of necessary new medical technologies, providing appropriate amounts in the budgets of the program of state guarantees and preferential drug provision for the population, with justification for calculating tariffs.